TumorDiagnostik & Therapie, Table of Contents TumorDiagnostik & Therapie 2017; 38(03): 172-177DOI: 10.1055/s-0043-101185 Schwerpunkt Neuroonkologie © Georg Thieme Verlag KG Stuttgart · New York Maligne Gliome: Therapieoptionen bei Kindern und Jugendlichen André O. von Bueren 1 Unité d´onco-hématologie pédiatrique, Departement de l´enfant et de l´adolescent, Hôpitaux Universitaire Genève, Genf, Schweiz , Maria Wiese 2 Abteilung für Pädiatrische Hämatologie und Onkologie, Universitätsmedizin Göttingen , Gerrit Gielen 3 Institut für Neuropathologie, Universitätsklinikum Bonn, Bonn , Christof M. Kramm 4 Abteilung für Pädiatrische Hämatologie und Onkologie, Universitätsmedizin Göttingen › Author Affiliations Recommend Article Abstract Buy Article Neben den Eckpfeilern einer konventionellen onkologischen Therapie – Tumoroperation, Radio- und Chemotherapie – beleuchtet dieser Beitrag auch zielgerichtete Therapiestrategien sowie die Neuentwicklungen im immuntherapeutischen Bereich speziell bei pädiatrischen hochgradigen Gliomen. Full Text References Literatur 1 Ostrom QT. Gittleman H. Fulop J. et al. CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2008–2012. Neuro Oncol 2015; 17: 1-62 2 Hargrave D. Bartels U. Bouffet E. Diffuse brainstem glioma in children: critical review of clinical trials. Lancet Oncol 2006; 7: 241-248 3 Castel D. Phillipe C. Calmon R. et al. Histone H3F3A and HIST1H3B K27M mutations define two subgroups of diffuse intrinsic pontine gliomas with different prognosis and phenotypes. Acta Neuropathol 2015; 130: 815-827 4 Louis DN. Perry A. Reifenberger G. et al. WHO classification of tumours of the central nervous system.Revised. 4th edition. Lyon: International Agency for Research on Cancer; 2016 5 Louis DN. WHO classification of tumours of the central nervous system. 4th ed. Lyon: International Agency for Research on Cancer; 2007 6 Duffner PK. Krischer JE. Burger PC. et al. Treatment of infants with malignant gliomas: the Pediatric Oncology Group experience. J Neurooncol 1996; 28: 245-256 7 Dufour C. Grill J. Lellouch-Tubiana A. et al. High-grade glioma in children under 5 years of age: a chemotherapy only approach with the BBSFOP protocol. Eur J Cancer 2006; 42: 2939-2945 8 Geyer JR. Finlay JL. Boyett JM. et al. Survival of infants with malignant astrocytomas. A Report from the Childrens Cancer Group. Cancer 1995; 75: 1045-1050 9 Albright AL. Sposto R. Holmes E. et al. Correlation of neurosurgical subspecialization with outcomes in children with malignant brain tumors. Neurosurgery 2000; 47: 879-887 10 Wisoff JH. Boyett JM. Berger MS. et al. Current neurosurgical management and the impact of the extent of resection in the treatment of malignant gliomas of childhood: a report of the Children's Cancer Group trial no. CCG-945. J Neurosurg 1998; 89: 52-59 11 Finlay JL. Wisoff JH. The impact of extent of resection in the management of malignant gliomas of childhood. Childs Nerv Syst 1999; 15: 786-788 12 Campbell JW. Pollack IF. Martinez AJ. et al. High-grade astrocytomas in children: radiologically complete resection is associated with an excellent long-term prognosis. Neurosurgery 1996; 38: 258-264 13 Kramm CM. Wagner S. van Gool S. et al. Improved survival after gross total resection of malignant gliomas in pediatric patients from the HIT-GBM studies. Anticancer Res 2006; 26: 3773-3779 14 Wolff JE. Gnekow AK. Kortmann RD. et al. Preradiation chemotherapy for pediatric patients with high-grade glioma. Cancer 2002; 94: 264-271 15 Kotecha RS. Burley K. Junckerstorff R. et al. Chemotherapy increases amenability of surgical resection in congenital glioblastoma. Pediatr Hematol Oncol 2012; 29: 538-544 16 Montemurro N. Second surgery for recurrent glioblastoma: A concise overview of the current literature. Clin Neurol Neurosurg 2016; 142: 60-64 17 Brandes AA. Bartolotti M. Tosoni A. et al. Patient outcomes following second surgery for recurrent glioblastoma. Future Oncol 2016; 12: 1039-1044 18 Giordano M. Samii A. Lawson McLean A. et al. Intraoperative magnetic resonance imaging in pediatric neurosurgery: safety and utility. J Neurosurg Pediatr 2017; 19: 77-84 19 Barbagallo GM. Certo F. Heiss K. et al. 5-ALA fluorescence-assisted surgery in pediatric brain tumors: report of three cases and review of the literature. Br J Neurosurg 2014; 28: 750-754 20 Preuß M. Renner C. Krupp W. et al. The use of 5-aminolevulinic acid fluorescence guidance in resection of pediatric brain tumors. Childs Nerv Syst 2013; 29: 1263-1267 21 Gillingham FJ. Yamashita J. The effect of radiotherapy for glioblastoma: a review of 516 cases (author's transl). No Shinkei Geka 1975; 3: 329-336 22 Sposto R. Ertel IJ. Jenkin RD. et al. The effectiveness of chemotherapy for treatment of high grade astrocytoma in children: Results of a randomized trial. J Neuro-Oncol 1989; 7: 165-177 23 Stupp R. Mason WP. van den Bent MJ. et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352: 987-996 24 Cohen KJ. Heidemann RL. Zhou T. et al. Temozolomide in the treatment of children with newly diagnosed diffuse intrinsic pontine gliomas: a report from the Children's Oncology Group. Neuro Oncol 2011; 13: 410-416 25 Cohen KJ. Pollack IF. Zhou T. et al. Temozolomide in the treatment of high-grade gliomas in children: a report from the Children's Oncology Group. Neuro Oncol 2011; 13: 317-323 26 Morales La Madrid A. Hashizume R. Kieran MW. Future Clinical Trials in DIPG: Bringing Epigenetics to the Clinic. Front Oncol 2015; 5: 148 27 Jakacki RI. Cohen KJ. Buxton A. et al. Phase 2 study of concurrent radiotherapy and temozolomide followed by temozolomide and lomustine in the treatment of children with high-grade glioma: a report of the Children's Oncology Group ACNS0423 study. Neuro Oncol 2016; 18: 1442-1450 28 Hegi ME. Diserens AC. Gorlia T. et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005; 352: 997-1003 29 Janssens GO. Gandola L. Bolle S. et al. Survival benefit for patients with DIPG undergoing re-irradiation at first progression: a matched-cohort analysis on behalf of the SIOP-E-HGG/DIPG working group. Eur J Cancer 2017; 73: 38-47 30 Muller K. Scheithauer H. Pietschmann S. et al. Reirradiation as part of a salvage treatment approach for progressive non-pontine pediatric high-grade gliomas: preliminary experiences from the German HIT-HGG study group. Radiat Oncol 2014; 9: 177 31 Leroy R. Proton Therapy in Children: A Systematic Review of Clinical Effectiveness in 15 Pediatric Cancers. Int J Radiat Oncol Biol Phys 2016; 95: 267-278 32 Jones C. Karajannis MA. Jones DTW. et al. Pediatric high-grade glioma: biologically and clinically in need of new thinking. Neuro Oncol 2016; 33 https://www.dkfz.de/en/inform 34 Ardon H. de Vleeschouwer S. van Calenbergh F. et al. Adjuvant dendritic cell-based tumour vaccination for children with malignant brain tumours. Pediatr Blood Cancer 2010; 54: 519-525 35 Rutkowski S. de Vleeschouwer S. Kaempgen E. et al. Surgery and adjuvant dendritic cell-based tumour vaccination for patients with relapsed malignant glioma, a feasibility study. Br J Cancer 2004; 91: 1656-1662 36 Freeman AI. Zakay-Rones Z. Gomori JM. et al. Phase I/II trial of intravenous NDV-HUJ oncolytic virus in recurrent glioblastoma multiforme. Mol Ther 2006; 13: 221-228 37 Brown CE. Alizadeh D. Starr R. et al. Regression of glioblastoma after chimeric antigen receptor T-cell therapy. N Engl J Med 2016; 375: 2561-2569 38 Bouffet E. Larouche V. Campbell BB. et al. Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair Deficiency. J Clin Oncol 2016; 34: 2206-2211 39 Bender S. Gronych J. Warnatz HJ. et al. Recurrent MET fusion genes represent a drug target in pediatric glioblastoma. Nat Med 2016; 22: 1314-1320
